This site is intended for U.S. Healthcare Professionals only.
CAMZYOS® is the first and only approved cardiac myosin inhibitor that targets HCM at the source.1,2
CAMZYOS is an allosteric and reversible inhibitor selective for cardiac myosin that helps to modulate the number of myosin heads in the off state.
This reduces the number of myosin-actin cross-bridges that form.1
SRT=septal reduction therapy.
This website is best viewed
using the horizontal display
on your tablet device.
This website is best viewed
using the vertical display
on your mobile device.
References: